Amneal Pharmaceuticals, Inc. Stock Analysis & AI Score
Amneal Pharmaceuticals, Inc. (AMRX) has an ST Score of 51.5 (C+), driven by its Momentum (A-) and held back by its Valuation (D-). Analysts rate it Buy with a $23.20 price target (+17.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Amneal Pharmaceuticals, Inc. (AMRX) has an ST Score of 51.5 (C+), driven by its Momentum (A-) and held back by its Valuation (D-). Analysts rate it Buy with a $23.20 price target (+17.1% upside).
- Strongest
- MomentumA-
- Weakest
- ValuationD-
All factor grades
- MomentumA-
- ProfitabilityB+
- ForecastB-
- GrowthC+
- SentimentC+
- Financial StrengthD+
- ValuationD-
- Piotroski7/9
Contact
AMRX stock: frequently asked questions
What is AMRX's ST Score?
Amneal Pharmaceuticals, Inc. (AMRX) has an ST Score of 51.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AMRX a buy, hold, or sell?
Analysts rate AMRX a Buy, with a price target of $23.20 (+17.1% vs the current price). Our ST Score grades it C+ (51.5/100). The ST Score is a data-driven signal, not a recommendation.
What are AMRX's factor grades?
Valuation D-, Profitability B+, Financial Strength D+, Momentum A-, Growth C+, Forecast B-, Sentiment C+.
What is AMRX's valuation grade?
Amneal Pharmaceuticals, Inc. (AMRX) earns a valuation grade of D-, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AMRX's growth grade?
Amneal Pharmaceuticals, Inc. (AMRX) earns a growth grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AMRX's profitability grade?
Amneal Pharmaceuticals, Inc. (AMRX) earns a profitability grade of B+, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AMRX's financial strength grade?
Amneal Pharmaceuticals, Inc. (AMRX) earns a financial strength grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AMRX?
The average analyst price target for Amneal Pharmaceuticals, Inc. (AMRX) is $23.20 from 17 analysts, which is +17.1% versus the recent price of $19.80.
What is AMRX's Piotroski score?
Amneal Pharmaceuticals, Inc. (AMRX) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.